The Experts below are selected from a list of 90702 Experts worldwide ranked by ideXlab platform
James Mason - One of the best experts on this subject based on the ideXlab platform.
-
The Cochrane Library - Treatment discontinuation with selective serotonin Reuptake inhibitors (SSRIs) versus tricyclic antidepressants (TCAs)
The Cochrane database of systematic reviews, 2007Co-Authors: Corrado Barbui, Nick Freemantle, Matthew Hotopf, J Boynton, Rachel Churchill, John R. Geddes, Rebecca Hardy, Glyn Lewis, Martin P Eccles, James MasonAbstract:Selective serotonin Reuptake inhibitors are thought to have better discontinuation rates (i.e. less people dropping out) than tricyclic and heterocyclic antidepressant drugs. It is important to quantify the drop-out rates of different antidepressant drugs in order to have a better understanding of the relative tolerability of these drugs. To assess the comparative tolerability of selective serotonin Reuptake inhibitors and tricyclic/heterocyclic antidepressant drugs. We searched the Cochrane Collaboration Depression, Anxiety and Neurosis Controlled Trials Registers (1997 to 1999), MEDLINE (1966 to 1999), EMBASE (1974 to 1999) We also searched specialist journals, the reference lists of relevant papers and previous systematic reviews, conference abstracts and government documents. Representatives of the pharmaceutical industry were contacted. Parallel group randomised controlled trials comparing selective serotonin Reuptake inhibitors with tricyclic or heterocyclic antidepressants in people with depression. Two reviewers independently extracted data and a third reviewer checked any cases of disagreement. We included 136 trials. The selective serotonin Reuptake inhibitors showed less participants dropping out compared to the tricyclic/heterocyclic group (odds ratio 1.21, 95% confidence interval 1.12 to 1.30). A statistically significant difference was found in total drop-outs between the selective serotonin Reuptake inhibitors and the old tricyclics as well as the newer tricyclics. When the selective serotonin Reuptake inhibitors were compared to the heterocyclic antidepressants, there was a non significant difference favouring the selective serotonin Reuptake inhibitors. The poor tolerability profile of the old tricyclics was explained by differences in drop-outs for side-effects, but not for inefficacy. Whilst selective serotonin Reuptake inhibitors do appear to show an advantage over tricyclic drugs in terms of total drop-outs, this advantage is relatively modest. This has implications for pharmaco-economic models, some of which may have overestimated the difference of drop-out rates between selective serotonin Reuptake inhibitors and tricyclic antidepressants. These results are based on short-term randomised controlled trials, and may not generalise into clinical practice.
-
The Cochrane Library - Treatment discontinuation with selective serotonin Reuptake inhibitors (SSRIs) versus tricyclic antidepressants (TCAs)
Cochrane Database of Systematic Reviews, 2007Co-Authors: Corrado Barbui, Nick Freemantle, Matthew Hotopf, J Boynton, Rachel Churchill, John R. Geddes, Rebecca Hardy, Glyn Lewis, Martin P Eccles, James MasonAbstract:BACKGROUND: Selective serotonin Reuptake inhibitors are thought to have better discontinuation rates (i.e. less people dropping out) than tricyclic and heterocyclic antidepressant drugs. It is important to quantify the drop-out rates of different antidepressant drugs in order to have a better understanding of the relative tolerability of these drugs. OBJECTIVES: To assess the comparative tolerability of selective serotonin Reuptake inhibitors and tricyclic/heterocyclic antidepressant drugs. SEARCH STRATEGY: We searched the Cochrane Collaboration Depression, Anxiety and Neurosis Controlled Trials Registers (1997 to 1999), MEDLINE (1966 to 1999), EMBASE (1974 to 1999) We also searched specialist journals, the reference lists of relevant papers and previous systematic reviews, conference abstracts and government documents. Representatives of the pharmaceutical industry were contacted. SELECTION CRITERIA: Parallel group randomised controlled trials comparing selective serotonin Reuptake inhibitors with tricyclic or heterocyclic antidepressants in people with depression. DATA COLLECTION AND ANALYSIS: Two reviewers independently extracted data and a third reviewer checked any cases of disagreement. MAIN RESULTS: We included 136 trials. The selective serotonin Reuptake inhibitors showed less participants dropping out compared to the tricyclic/heterocyclic group (odds ratio 1.21, 95% confidence interval 1.12 to 1.30). A statistically significant difference was found in total drop-outs between the selective serotonin Reuptake inhibitors and the old tricyclics as well as the newer tricyclics. When the selective serotonin Reuptake inhibitors were compared to the heterocyclic antidepressants, there was a non significant difference favouring the selective serotonin Reuptake inhibitors. The poor tolerability profile of the old tricyclics was explained by differences in drop-outs for side-effects, but not for inefficacy. AUTHORS' CONCLUSIONS: Whilst selective serotonin Reuptake inhibitors do appear to show an advantage over tricyclic drugs in terms of total drop-outs, this advantage is relatively modest. This has implications for pharmaco-economic models, some of which may have overestimated the difference of drop-out rates between selective serotonin Reuptake inhibitors and tricyclic antidepressants. These results are based on short-term randomised controlled trials, and may not generalise into clinical practice.
-
treatment discontinuation with selective serotonin Reuptake inhibitors ssris versus tricyclic antidepressants tcas
Cochrane Database of Systematic Reviews, 2006Co-Authors: Corrado Barbui, Nick Freemantle, Matthew Hotopf, J Boynton, Rachel Churchill, John R. Geddes, Rebecca Hardy, Glyn Lewis, Martin P Eccles, James MasonAbstract:BACKGROUND: Selective serotonin Reuptake inhibitors are thought to have better discontinuation rates (i.e. less people dropping out) than tricyclic and heterocyclic antidepressant drugs. It is important to quantify the drop-out rates of different antidepressant drugs in order to have a better understanding of the relative tolerability of these drugs. OBJECTIVES: To assess the comparative tolerability of selective serotonin Reuptake inhibitors and tricyclic/heterocyclic antidepressant drugs. SEARCH STRATEGY: We searched the Cochrane Collaboration Depression, Anxiety and Neurosis Controlled Trials Registers (1997 to 1999), MEDLINE (1966 to 1999), EMBASE (1974 to 1999) We also searched specialist journals, the reference lists of relevant papers and previous systematic reviews, conference abstracts and government documents. Representatives of the pharmaceutical industry were contacted. SELECTION CRITERIA: Parallel group randomised controlled trials comparing selective serotonin Reuptake inhibitors with tricyclic or heterocyclic antidepressants in people with depression. DATA COLLECTION AND ANALYSIS: Two reviewers independently extracted data and a third reviewer checked any cases of disagreement. MAIN RESULTS: We included 136 trials. The selective serotonin Reuptake inhibitors showed less participants dropping out compared to the tricyclic/heterocyclic group (odds ratio 1.21, 95% confidence interval 1.12 to 1.30). A statistically significant difference was found in total drop-outs between the selective serotonin Reuptake inhibitors and the old tricyclics as well as the newer tricyclics. When the selective serotonin Reuptake inhibitors were compared to the heterocyclic antidepressants, there was a non significant difference favouring the selective serotonin Reuptake inhibitors. The poor tolerability profile of the old tricyclics was explained by differences in drop-outs for side-effects, but not for inefficacy. AUTHORS' CONCLUSIONS: Whilst selective serotonin Reuptake inhibitors do appear to show an advantage over tricyclic drugs in terms of total drop-outs, this advantage is relatively modest. This has implications for pharmaco-economic models, some of which may have overestimated the difference of drop-out rates between selective serotonin Reuptake inhibitors and tricyclic antidepressants. These results are based on short-term randomised controlled trials, and may not generalise into clinical practice.
-
Selective serotonin Reuptake inhibitors versus tricyclic and heterocyclic antidepressants: comparison of drug adherence.
The Cochrane database of systematic reviews, 2000Co-Authors: Corrado Barbui, Nick Freemantle, Matthew Hotopf, J Boynton, Rachel Churchill, M Eccles, John R. Geddes, Rebecca Hardy, Glyn Lewis, James MasonAbstract:Selective serotonin Reuptake inhibitors are thought to have better discontinuation rates (i.e. less people dropping out) than tricyclic and heterocyclic antidepressant drugs. It is important to quantify the drop-out rates of different antidepressant drugs in order to have a better understanding of the relative tolerability of these drugs. To assess the comparative tolerability of selective serotonin Reuptake inhibitors and tricyclic/heterocyclic antidepressant drugs. We searched the Cochrane Collaboration Depression, Anxiety and Neurosis Controlled Trials Registers (1997 to 1999), MEDLINE (1966 to 1999), EMBASE (1974 to 1999) We also searched specialist journals, the reference lists of relevant papers and previous systematic reviews, conference abstracts and government documents. Representatives of the pharmaceutical industry were contacted. Parallel group randomised controlled trials comparing selective serotonin Reuptake inhibitors with tricyclic or heterocyclic antidepressants in people with depression. Two reviewers independently extracted data and a third reviewer checked any cases of disagreement. We included 136 trials. The selective serotonin Reuptake inhibitors showed less participants dropping out compared to the tricyclic/heterocyclic group (odds ratio 1.21, 95% confidence interval 1.12 to 1.30). A statistically significant difference was found in total drop-outs between the selective serotonin Reuptake inhibitors and the old tricyclics as well as the newer tricyclics. When the selective serotonin Reuptake inhibitors were compared to the heterocyclic antidepressants, there was a non significant difference favouring the selective serotonin Reuptake inhibitors. The poor tolerability profile of the old tricyclics was explained by differences in drop-outs for side-effects, but not for inefficacy. Whilst selective serotonin Reuptake inhibitors do appear to show an advantage over tricyclic drugs in terms of total drop-outs, this advantage is relatively modest. This has implications for pharmaco-economic models, some of which may have overestimated the difference of drop-out rates between selective serotonin Reuptake inhibitors and tricyclic antdepressants. These results are based on short-term randomised controlled trials, and may not generalise into clinical practice.
-
selective serotonin Reuptake inhibitors versus tricyclic and heterocyclic antidepressants comparison of drug adherence
Cochrane Database of Systematic Reviews, 2000Co-Authors: Corrado Barbui, Nick Freemantle, Matthew Hotopf, J Boynton, Rachel Churchill, M Eccles, John R. Geddes, Rebecca Hardy, Glyn Lewis, James MasonAbstract:BACKGROUND: Selective serotonin Reuptake inhibitors are thought to have better discontinuation rates (i.e. less people dropping out) than tricyclic and heterocyclic antidepressant drugs. It is important to quantify the drop-out rates of different antidepressant drugs in order to have a better understanding of the relative tolerability of these drugs. OBJECTIVES: To assess the comparative tolerability of selective serotonin Reuptake inhibitors and tricyclic/heterocyclic antidepressant drugs. SEARCH STRATEGY: We searched the Cochrane Collaboration Depression, Anxiety and Neurosis Controlled Trials Registers (1997 to 1999), MEDLINE (1966 to 1999), EMBASE (1974 to 1999) We also searched specialist journals, the reference lists of relevant papers and previous systematic reviews, conference abstracts and government documents. Representatives of the pharmaceutical industry were contacted. SELECTION CRITERIA: Parallel group randomised controlled trials comparing selective serotonin Reuptake inhibitors with tricyclic or heterocyclic antidepressants in people with depression. DATA COLLECTION AND ANALYSIS: Two reviewers independently extracted data and a third reviewer checked any cases of disagreement. MAIN RESULTS: We included 136 trials. The selective serotonin Reuptake inhibitors showed less participants dropping out compared to the tricyclic/heterocyclic group (odds ratio 1.21, 95% confidence interval 1.12 to 1.30). A statistically significant difference was found in total drop-outs between the selective serotonin Reuptake inhibitors and the old tricyclics as well as the newer tricyclics. When the selective serotonin Reuptake inhibitors were compared to the heterocyclic antidepressants, there was a non significant difference favouring the selective serotonin Reuptake inhibitors. The poor tolerability profile of the old tricyclics was explained by differences in drop-outs for side-effects, but not for inefficacy. REVIEWER'S CONCLUSIONS: Whilst selective serotonin Reuptake inhibitors do appear to show an advantage over tricyclic drugs in terms of total drop-outs, this advantage is relatively modest. This has implications for pharmaco-economic models, some of which may have overestimated the difference of drop-out rates between selective serotonin Reuptake inhibitors and tricyclic antdepressants. These results are based on short-term randomised controlled trials, and may not generalise into clinical practice.
Corrado Barbui - One of the best experts on this subject based on the ideXlab platform.
-
The Cochrane Library - Treatment discontinuation with selective serotonin Reuptake inhibitors (SSRIs) versus tricyclic antidepressants (TCAs)
The Cochrane database of systematic reviews, 2007Co-Authors: Corrado Barbui, Nick Freemantle, Matthew Hotopf, J Boynton, Rachel Churchill, John R. Geddes, Rebecca Hardy, Glyn Lewis, Martin P Eccles, James MasonAbstract:Selective serotonin Reuptake inhibitors are thought to have better discontinuation rates (i.e. less people dropping out) than tricyclic and heterocyclic antidepressant drugs. It is important to quantify the drop-out rates of different antidepressant drugs in order to have a better understanding of the relative tolerability of these drugs. To assess the comparative tolerability of selective serotonin Reuptake inhibitors and tricyclic/heterocyclic antidepressant drugs. We searched the Cochrane Collaboration Depression, Anxiety and Neurosis Controlled Trials Registers (1997 to 1999), MEDLINE (1966 to 1999), EMBASE (1974 to 1999) We also searched specialist journals, the reference lists of relevant papers and previous systematic reviews, conference abstracts and government documents. Representatives of the pharmaceutical industry were contacted. Parallel group randomised controlled trials comparing selective serotonin Reuptake inhibitors with tricyclic or heterocyclic antidepressants in people with depression. Two reviewers independently extracted data and a third reviewer checked any cases of disagreement. We included 136 trials. The selective serotonin Reuptake inhibitors showed less participants dropping out compared to the tricyclic/heterocyclic group (odds ratio 1.21, 95% confidence interval 1.12 to 1.30). A statistically significant difference was found in total drop-outs between the selective serotonin Reuptake inhibitors and the old tricyclics as well as the newer tricyclics. When the selective serotonin Reuptake inhibitors were compared to the heterocyclic antidepressants, there was a non significant difference favouring the selective serotonin Reuptake inhibitors. The poor tolerability profile of the old tricyclics was explained by differences in drop-outs for side-effects, but not for inefficacy. Whilst selective serotonin Reuptake inhibitors do appear to show an advantage over tricyclic drugs in terms of total drop-outs, this advantage is relatively modest. This has implications for pharmaco-economic models, some of which may have overestimated the difference of drop-out rates between selective serotonin Reuptake inhibitors and tricyclic antidepressants. These results are based on short-term randomised controlled trials, and may not generalise into clinical practice.
-
The Cochrane Library - Treatment discontinuation with selective serotonin Reuptake inhibitors (SSRIs) versus tricyclic antidepressants (TCAs)
Cochrane Database of Systematic Reviews, 2007Co-Authors: Corrado Barbui, Nick Freemantle, Matthew Hotopf, J Boynton, Rachel Churchill, John R. Geddes, Rebecca Hardy, Glyn Lewis, Martin P Eccles, James MasonAbstract:BACKGROUND: Selective serotonin Reuptake inhibitors are thought to have better discontinuation rates (i.e. less people dropping out) than tricyclic and heterocyclic antidepressant drugs. It is important to quantify the drop-out rates of different antidepressant drugs in order to have a better understanding of the relative tolerability of these drugs. OBJECTIVES: To assess the comparative tolerability of selective serotonin Reuptake inhibitors and tricyclic/heterocyclic antidepressant drugs. SEARCH STRATEGY: We searched the Cochrane Collaboration Depression, Anxiety and Neurosis Controlled Trials Registers (1997 to 1999), MEDLINE (1966 to 1999), EMBASE (1974 to 1999) We also searched specialist journals, the reference lists of relevant papers and previous systematic reviews, conference abstracts and government documents. Representatives of the pharmaceutical industry were contacted. SELECTION CRITERIA: Parallel group randomised controlled trials comparing selective serotonin Reuptake inhibitors with tricyclic or heterocyclic antidepressants in people with depression. DATA COLLECTION AND ANALYSIS: Two reviewers independently extracted data and a third reviewer checked any cases of disagreement. MAIN RESULTS: We included 136 trials. The selective serotonin Reuptake inhibitors showed less participants dropping out compared to the tricyclic/heterocyclic group (odds ratio 1.21, 95% confidence interval 1.12 to 1.30). A statistically significant difference was found in total drop-outs between the selective serotonin Reuptake inhibitors and the old tricyclics as well as the newer tricyclics. When the selective serotonin Reuptake inhibitors were compared to the heterocyclic antidepressants, there was a non significant difference favouring the selective serotonin Reuptake inhibitors. The poor tolerability profile of the old tricyclics was explained by differences in drop-outs for side-effects, but not for inefficacy. AUTHORS' CONCLUSIONS: Whilst selective serotonin Reuptake inhibitors do appear to show an advantage over tricyclic drugs in terms of total drop-outs, this advantage is relatively modest. This has implications for pharmaco-economic models, some of which may have overestimated the difference of drop-out rates between selective serotonin Reuptake inhibitors and tricyclic antidepressants. These results are based on short-term randomised controlled trials, and may not generalise into clinical practice.
-
treatment discontinuation with selective serotonin Reuptake inhibitors ssris versus tricyclic antidepressants tcas
Cochrane Database of Systematic Reviews, 2006Co-Authors: Corrado Barbui, Nick Freemantle, Matthew Hotopf, J Boynton, Rachel Churchill, John R. Geddes, Rebecca Hardy, Glyn Lewis, Martin P Eccles, James MasonAbstract:BACKGROUND: Selective serotonin Reuptake inhibitors are thought to have better discontinuation rates (i.e. less people dropping out) than tricyclic and heterocyclic antidepressant drugs. It is important to quantify the drop-out rates of different antidepressant drugs in order to have a better understanding of the relative tolerability of these drugs. OBJECTIVES: To assess the comparative tolerability of selective serotonin Reuptake inhibitors and tricyclic/heterocyclic antidepressant drugs. SEARCH STRATEGY: We searched the Cochrane Collaboration Depression, Anxiety and Neurosis Controlled Trials Registers (1997 to 1999), MEDLINE (1966 to 1999), EMBASE (1974 to 1999) We also searched specialist journals, the reference lists of relevant papers and previous systematic reviews, conference abstracts and government documents. Representatives of the pharmaceutical industry were contacted. SELECTION CRITERIA: Parallel group randomised controlled trials comparing selective serotonin Reuptake inhibitors with tricyclic or heterocyclic antidepressants in people with depression. DATA COLLECTION AND ANALYSIS: Two reviewers independently extracted data and a third reviewer checked any cases of disagreement. MAIN RESULTS: We included 136 trials. The selective serotonin Reuptake inhibitors showed less participants dropping out compared to the tricyclic/heterocyclic group (odds ratio 1.21, 95% confidence interval 1.12 to 1.30). A statistically significant difference was found in total drop-outs between the selective serotonin Reuptake inhibitors and the old tricyclics as well as the newer tricyclics. When the selective serotonin Reuptake inhibitors were compared to the heterocyclic antidepressants, there was a non significant difference favouring the selective serotonin Reuptake inhibitors. The poor tolerability profile of the old tricyclics was explained by differences in drop-outs for side-effects, but not for inefficacy. AUTHORS' CONCLUSIONS: Whilst selective serotonin Reuptake inhibitors do appear to show an advantage over tricyclic drugs in terms of total drop-outs, this advantage is relatively modest. This has implications for pharmaco-economic models, some of which may have overestimated the difference of drop-out rates between selective serotonin Reuptake inhibitors and tricyclic antidepressants. These results are based on short-term randomised controlled trials, and may not generalise into clinical practice.
-
Selective serotonin Reuptake inhibitors versus tricyclic and heterocyclic antidepressants: comparison of drug adherence.
The Cochrane database of systematic reviews, 2000Co-Authors: Corrado Barbui, Nick Freemantle, Matthew Hotopf, J Boynton, Rachel Churchill, M Eccles, John R. Geddes, Rebecca Hardy, Glyn Lewis, James MasonAbstract:Selective serotonin Reuptake inhibitors are thought to have better discontinuation rates (i.e. less people dropping out) than tricyclic and heterocyclic antidepressant drugs. It is important to quantify the drop-out rates of different antidepressant drugs in order to have a better understanding of the relative tolerability of these drugs. To assess the comparative tolerability of selective serotonin Reuptake inhibitors and tricyclic/heterocyclic antidepressant drugs. We searched the Cochrane Collaboration Depression, Anxiety and Neurosis Controlled Trials Registers (1997 to 1999), MEDLINE (1966 to 1999), EMBASE (1974 to 1999) We also searched specialist journals, the reference lists of relevant papers and previous systematic reviews, conference abstracts and government documents. Representatives of the pharmaceutical industry were contacted. Parallel group randomised controlled trials comparing selective serotonin Reuptake inhibitors with tricyclic or heterocyclic antidepressants in people with depression. Two reviewers independently extracted data and a third reviewer checked any cases of disagreement. We included 136 trials. The selective serotonin Reuptake inhibitors showed less participants dropping out compared to the tricyclic/heterocyclic group (odds ratio 1.21, 95% confidence interval 1.12 to 1.30). A statistically significant difference was found in total drop-outs between the selective serotonin Reuptake inhibitors and the old tricyclics as well as the newer tricyclics. When the selective serotonin Reuptake inhibitors were compared to the heterocyclic antidepressants, there was a non significant difference favouring the selective serotonin Reuptake inhibitors. The poor tolerability profile of the old tricyclics was explained by differences in drop-outs for side-effects, but not for inefficacy. Whilst selective serotonin Reuptake inhibitors do appear to show an advantage over tricyclic drugs in terms of total drop-outs, this advantage is relatively modest. This has implications for pharmaco-economic models, some of which may have overestimated the difference of drop-out rates between selective serotonin Reuptake inhibitors and tricyclic antdepressants. These results are based on short-term randomised controlled trials, and may not generalise into clinical practice.
-
selective serotonin Reuptake inhibitors versus tricyclic and heterocyclic antidepressants comparison of drug adherence
Cochrane Database of Systematic Reviews, 2000Co-Authors: Corrado Barbui, Nick Freemantle, Matthew Hotopf, J Boynton, Rachel Churchill, M Eccles, John R. Geddes, Rebecca Hardy, Glyn Lewis, James MasonAbstract:BACKGROUND: Selective serotonin Reuptake inhibitors are thought to have better discontinuation rates (i.e. less people dropping out) than tricyclic and heterocyclic antidepressant drugs. It is important to quantify the drop-out rates of different antidepressant drugs in order to have a better understanding of the relative tolerability of these drugs. OBJECTIVES: To assess the comparative tolerability of selective serotonin Reuptake inhibitors and tricyclic/heterocyclic antidepressant drugs. SEARCH STRATEGY: We searched the Cochrane Collaboration Depression, Anxiety and Neurosis Controlled Trials Registers (1997 to 1999), MEDLINE (1966 to 1999), EMBASE (1974 to 1999) We also searched specialist journals, the reference lists of relevant papers and previous systematic reviews, conference abstracts and government documents. Representatives of the pharmaceutical industry were contacted. SELECTION CRITERIA: Parallel group randomised controlled trials comparing selective serotonin Reuptake inhibitors with tricyclic or heterocyclic antidepressants in people with depression. DATA COLLECTION AND ANALYSIS: Two reviewers independently extracted data and a third reviewer checked any cases of disagreement. MAIN RESULTS: We included 136 trials. The selective serotonin Reuptake inhibitors showed less participants dropping out compared to the tricyclic/heterocyclic group (odds ratio 1.21, 95% confidence interval 1.12 to 1.30). A statistically significant difference was found in total drop-outs between the selective serotonin Reuptake inhibitors and the old tricyclics as well as the newer tricyclics. When the selective serotonin Reuptake inhibitors were compared to the heterocyclic antidepressants, there was a non significant difference favouring the selective serotonin Reuptake inhibitors. The poor tolerability profile of the old tricyclics was explained by differences in drop-outs for side-effects, but not for inefficacy. REVIEWER'S CONCLUSIONS: Whilst selective serotonin Reuptake inhibitors do appear to show an advantage over tricyclic drugs in terms of total drop-outs, this advantage is relatively modest. This has implications for pharmaco-economic models, some of which may have overestimated the difference of drop-out rates between selective serotonin Reuptake inhibitors and tricyclic antdepressants. These results are based on short-term randomised controlled trials, and may not generalise into clinical practice.
Chitoshi Itakura - One of the best experts on this subject based on the ideXlab platform.
-
Additive subthreshold dose effects of cannabinoid CB1 receptor antagonist and selective serotonin Reuptake inhibitor in antidepressant behavioral tests
European Journal of Pharmacology, 2008Co-Authors: Eiki Takahashi, Mariko Katayama, Kimie Niimi, Chitoshi ItakuraAbstract:Abstract The main clinically used antidepressant drugs are selective monoamine Reuptake inhibitors, including selective serotonin Reuptake inhibitors (citalopram, sertraline), selective dopamine Reuptake inhibitor (nomifensine) and selective noradrenaline Reuptake inhibitor (reboxetine), but they have various side effects. Because cannabinoid CB1 receptor antagonists (SR141716A, AM251) enhance monoamine release, they might be beneficial in the therapy of affective disorders. We hypothesized that the use of monoamine Reuptake inhibitors in combination with cannabinoid CB1 receptor antagonists would allow a lower dose of monoamine Reuptake inhibitors to be used in the therapy of depression, thereby reducing or eliminating the side effects. To test this hypothesis, we examined the combination of SR141716A or AM251 with citalopram, sertraline, nomifensine or reboxetine at subthreshold doses to see whether these combinations would show an additive effect in the forced swimming test and the tail suspension test with mice. Subthreshold doses of cannabinoid CB1 receptor antagonist and selective serotonin Reuptake inhibitors, which separately had no effect on the immobility of mice in the tests, showed a clear effect when the drugs were administered at 40 and 30 min, respectively, before the tests, without any change of motor activity. Therefore, the use of subthreshold doses of these agents in combination might be useful to enhance mainly serotonergic neurotransmission, and to reduce or eliminate the side effects of citalopram and sertraline.
-
Additive subthreshold dose effects of cannabinoid CB(1) receptor antagonist and selective serotonin Reuptake inhibitor in antidepressant behavioral tests.
European journal of pharmacology, 2008Co-Authors: Eiki Takahashi, Mariko Katayama, Kimie Niimi, Chitoshi ItakuraAbstract:The main clinically used antidepressant drugs are selective monoamine Reuptake inhibitors, including selective serotonin Reuptake inhibitors (citalopram, sertraline), selective dopamine Reuptake inhibitor (nomifensine) and selective noradrenaline Reuptake inhibitor (reboxetine), but they have various side effects. Because cannabinoid CB(1) receptor antagonists (SR141716A, AM251) enhance monoamine release, they might be beneficial in the therapy of affective disorders. We hypothesized that the use of monoamine Reuptake inhibitors in combination with cannabinoid CB(1) receptor antagonists would allow a lower dose of monoamine Reuptake inhibitors to be used in the therapy of depression, thereby reducing or eliminating the side effects. To test this hypothesis, we examined the combination of SR141716A or AM251 with citalopram, sertraline, nomifensine or reboxetine at subthreshold doses to see whether these combinations would show an additive effect in the forced swimming test and the tail suspension test with mice. Subthreshold doses of cannabinoid CB(1) receptor antagonist and selective serotonin Reuptake inhibitors, which separately had no effect on the immobility of mice in the tests, showed a clear effect when the drugs were administered at 40 and 30 min, respectively, before the tests, without any change of motor activity. Therefore, the use of subthreshold doses of these agents in combination might be useful to enhance mainly serotonergic neurotransmission, and to reduce or eliminate the side effects of citalopram and sertraline.
Seung Hoon Cheon - One of the best experts on this subject based on the ideXlab platform.
-
Triple Reuptake inhibitors: Design, synthesis and structure-activity relationship of benzylpiperidine-tetrazoles.
Bioorganic & Medicinal Chemistry, 2017Co-Authors: Suresh Paudel, Srijan Acharya, Goo Yoon, Daulat Bikram Khadka, Seung Hoon CheonAbstract:Abstract Monoamine transporters are important targets in the treatment of various central nervous disorders. Several limitations of traditional Reuptake inhibitors, like delayed onset of action, insomnia, and sexual dysfunction, have compelled the search for safer, more effective compounds. In this study, we have sought to identify novel monoamine Reuptake inhibitors. Based upon the docking study of compounds that we had reported previously, aromatic rings (A1) were modified to generate a novel series of benzylpiperidine–tetrazoles. Thirty-one compounds were synthesized and evaluated for their triple Reuptake inhibition of serotonin, norepinephrine and dopamine. Triple Reuptake inhibitor, compound 2q , in particular, showed potent serotonin Reuptake inhibition, validating our design approach.
-
exploration of substituted arylpiperazine tetrazoles as promising dual norepinephrine and dopamine Reuptake inhibitors
Bioorganic & Medicinal Chemistry, 2016Co-Authors: Suresh Paudel, Srijan Acharya, Goo Yoon, Kyeongman Kim, Seung Hoon CheonAbstract:In the search for potent dual norepinephrine and dopamine Reuptake inhibitors, several substituted arylpiperazine–tetrazoles were designed, synthesized and evaluated for their neurotransmitter Reuptake inhibitory activities. Various derivatives exhibited selective and strong neurotransmitter Reuptake inhibitory activity. In particular, compounds with a three-carbon linker displayed selective and stronger potency than those with two-carbon and four-carbon linkers. Interestingly, six compounds, 9b, 9c, 9d, 9o, 9q and 9u displayed more effective activity than the standard drug, bupropion. The provided SAR data and potent biological activity can offer useful guidelines for designing dual norepinephrine and dopamine Reuptake inhibitors as effective therapeutic agents for treatment of several central nervous system diseases.
Nick Freemantle - One of the best experts on this subject based on the ideXlab platform.
-
The Cochrane Library - Treatment discontinuation with selective serotonin Reuptake inhibitors (SSRIs) versus tricyclic antidepressants (TCAs)
The Cochrane database of systematic reviews, 2007Co-Authors: Corrado Barbui, Nick Freemantle, Matthew Hotopf, J Boynton, Rachel Churchill, John R. Geddes, Rebecca Hardy, Glyn Lewis, Martin P Eccles, James MasonAbstract:Selective serotonin Reuptake inhibitors are thought to have better discontinuation rates (i.e. less people dropping out) than tricyclic and heterocyclic antidepressant drugs. It is important to quantify the drop-out rates of different antidepressant drugs in order to have a better understanding of the relative tolerability of these drugs. To assess the comparative tolerability of selective serotonin Reuptake inhibitors and tricyclic/heterocyclic antidepressant drugs. We searched the Cochrane Collaboration Depression, Anxiety and Neurosis Controlled Trials Registers (1997 to 1999), MEDLINE (1966 to 1999), EMBASE (1974 to 1999) We also searched specialist journals, the reference lists of relevant papers and previous systematic reviews, conference abstracts and government documents. Representatives of the pharmaceutical industry were contacted. Parallel group randomised controlled trials comparing selective serotonin Reuptake inhibitors with tricyclic or heterocyclic antidepressants in people with depression. Two reviewers independently extracted data and a third reviewer checked any cases of disagreement. We included 136 trials. The selective serotonin Reuptake inhibitors showed less participants dropping out compared to the tricyclic/heterocyclic group (odds ratio 1.21, 95% confidence interval 1.12 to 1.30). A statistically significant difference was found in total drop-outs between the selective serotonin Reuptake inhibitors and the old tricyclics as well as the newer tricyclics. When the selective serotonin Reuptake inhibitors were compared to the heterocyclic antidepressants, there was a non significant difference favouring the selective serotonin Reuptake inhibitors. The poor tolerability profile of the old tricyclics was explained by differences in drop-outs for side-effects, but not for inefficacy. Whilst selective serotonin Reuptake inhibitors do appear to show an advantage over tricyclic drugs in terms of total drop-outs, this advantage is relatively modest. This has implications for pharmaco-economic models, some of which may have overestimated the difference of drop-out rates between selective serotonin Reuptake inhibitors and tricyclic antidepressants. These results are based on short-term randomised controlled trials, and may not generalise into clinical practice.
-
The Cochrane Library - Treatment discontinuation with selective serotonin Reuptake inhibitors (SSRIs) versus tricyclic antidepressants (TCAs)
Cochrane Database of Systematic Reviews, 2007Co-Authors: Corrado Barbui, Nick Freemantle, Matthew Hotopf, J Boynton, Rachel Churchill, John R. Geddes, Rebecca Hardy, Glyn Lewis, Martin P Eccles, James MasonAbstract:BACKGROUND: Selective serotonin Reuptake inhibitors are thought to have better discontinuation rates (i.e. less people dropping out) than tricyclic and heterocyclic antidepressant drugs. It is important to quantify the drop-out rates of different antidepressant drugs in order to have a better understanding of the relative tolerability of these drugs. OBJECTIVES: To assess the comparative tolerability of selective serotonin Reuptake inhibitors and tricyclic/heterocyclic antidepressant drugs. SEARCH STRATEGY: We searched the Cochrane Collaboration Depression, Anxiety and Neurosis Controlled Trials Registers (1997 to 1999), MEDLINE (1966 to 1999), EMBASE (1974 to 1999) We also searched specialist journals, the reference lists of relevant papers and previous systematic reviews, conference abstracts and government documents. Representatives of the pharmaceutical industry were contacted. SELECTION CRITERIA: Parallel group randomised controlled trials comparing selective serotonin Reuptake inhibitors with tricyclic or heterocyclic antidepressants in people with depression. DATA COLLECTION AND ANALYSIS: Two reviewers independently extracted data and a third reviewer checked any cases of disagreement. MAIN RESULTS: We included 136 trials. The selective serotonin Reuptake inhibitors showed less participants dropping out compared to the tricyclic/heterocyclic group (odds ratio 1.21, 95% confidence interval 1.12 to 1.30). A statistically significant difference was found in total drop-outs between the selective serotonin Reuptake inhibitors and the old tricyclics as well as the newer tricyclics. When the selective serotonin Reuptake inhibitors were compared to the heterocyclic antidepressants, there was a non significant difference favouring the selective serotonin Reuptake inhibitors. The poor tolerability profile of the old tricyclics was explained by differences in drop-outs for side-effects, but not for inefficacy. AUTHORS' CONCLUSIONS: Whilst selective serotonin Reuptake inhibitors do appear to show an advantage over tricyclic drugs in terms of total drop-outs, this advantage is relatively modest. This has implications for pharmaco-economic models, some of which may have overestimated the difference of drop-out rates between selective serotonin Reuptake inhibitors and tricyclic antidepressants. These results are based on short-term randomised controlled trials, and may not generalise into clinical practice.
-
treatment discontinuation with selective serotonin Reuptake inhibitors ssris versus tricyclic antidepressants tcas
Cochrane Database of Systematic Reviews, 2006Co-Authors: Corrado Barbui, Nick Freemantle, Matthew Hotopf, J Boynton, Rachel Churchill, John R. Geddes, Rebecca Hardy, Glyn Lewis, Martin P Eccles, James MasonAbstract:BACKGROUND: Selective serotonin Reuptake inhibitors are thought to have better discontinuation rates (i.e. less people dropping out) than tricyclic and heterocyclic antidepressant drugs. It is important to quantify the drop-out rates of different antidepressant drugs in order to have a better understanding of the relative tolerability of these drugs. OBJECTIVES: To assess the comparative tolerability of selective serotonin Reuptake inhibitors and tricyclic/heterocyclic antidepressant drugs. SEARCH STRATEGY: We searched the Cochrane Collaboration Depression, Anxiety and Neurosis Controlled Trials Registers (1997 to 1999), MEDLINE (1966 to 1999), EMBASE (1974 to 1999) We also searched specialist journals, the reference lists of relevant papers and previous systematic reviews, conference abstracts and government documents. Representatives of the pharmaceutical industry were contacted. SELECTION CRITERIA: Parallel group randomised controlled trials comparing selective serotonin Reuptake inhibitors with tricyclic or heterocyclic antidepressants in people with depression. DATA COLLECTION AND ANALYSIS: Two reviewers independently extracted data and a third reviewer checked any cases of disagreement. MAIN RESULTS: We included 136 trials. The selective serotonin Reuptake inhibitors showed less participants dropping out compared to the tricyclic/heterocyclic group (odds ratio 1.21, 95% confidence interval 1.12 to 1.30). A statistically significant difference was found in total drop-outs between the selective serotonin Reuptake inhibitors and the old tricyclics as well as the newer tricyclics. When the selective serotonin Reuptake inhibitors were compared to the heterocyclic antidepressants, there was a non significant difference favouring the selective serotonin Reuptake inhibitors. The poor tolerability profile of the old tricyclics was explained by differences in drop-outs for side-effects, but not for inefficacy. AUTHORS' CONCLUSIONS: Whilst selective serotonin Reuptake inhibitors do appear to show an advantage over tricyclic drugs in terms of total drop-outs, this advantage is relatively modest. This has implications for pharmaco-economic models, some of which may have overestimated the difference of drop-out rates between selective serotonin Reuptake inhibitors and tricyclic antidepressants. These results are based on short-term randomised controlled trials, and may not generalise into clinical practice.
-
Selective serotonin Reuptake inhibitors versus tricyclic and heterocyclic antidepressants: comparison of drug adherence.
The Cochrane database of systematic reviews, 2000Co-Authors: Corrado Barbui, Nick Freemantle, Matthew Hotopf, J Boynton, Rachel Churchill, M Eccles, John R. Geddes, Rebecca Hardy, Glyn Lewis, James MasonAbstract:Selective serotonin Reuptake inhibitors are thought to have better discontinuation rates (i.e. less people dropping out) than tricyclic and heterocyclic antidepressant drugs. It is important to quantify the drop-out rates of different antidepressant drugs in order to have a better understanding of the relative tolerability of these drugs. To assess the comparative tolerability of selective serotonin Reuptake inhibitors and tricyclic/heterocyclic antidepressant drugs. We searched the Cochrane Collaboration Depression, Anxiety and Neurosis Controlled Trials Registers (1997 to 1999), MEDLINE (1966 to 1999), EMBASE (1974 to 1999) We also searched specialist journals, the reference lists of relevant papers and previous systematic reviews, conference abstracts and government documents. Representatives of the pharmaceutical industry were contacted. Parallel group randomised controlled trials comparing selective serotonin Reuptake inhibitors with tricyclic or heterocyclic antidepressants in people with depression. Two reviewers independently extracted data and a third reviewer checked any cases of disagreement. We included 136 trials. The selective serotonin Reuptake inhibitors showed less participants dropping out compared to the tricyclic/heterocyclic group (odds ratio 1.21, 95% confidence interval 1.12 to 1.30). A statistically significant difference was found in total drop-outs between the selective serotonin Reuptake inhibitors and the old tricyclics as well as the newer tricyclics. When the selective serotonin Reuptake inhibitors were compared to the heterocyclic antidepressants, there was a non significant difference favouring the selective serotonin Reuptake inhibitors. The poor tolerability profile of the old tricyclics was explained by differences in drop-outs for side-effects, but not for inefficacy. Whilst selective serotonin Reuptake inhibitors do appear to show an advantage over tricyclic drugs in terms of total drop-outs, this advantage is relatively modest. This has implications for pharmaco-economic models, some of which may have overestimated the difference of drop-out rates between selective serotonin Reuptake inhibitors and tricyclic antdepressants. These results are based on short-term randomised controlled trials, and may not generalise into clinical practice.
-
selective serotonin Reuptake inhibitors versus tricyclic and heterocyclic antidepressants comparison of drug adherence
Cochrane Database of Systematic Reviews, 2000Co-Authors: Corrado Barbui, Nick Freemantle, Matthew Hotopf, J Boynton, Rachel Churchill, M Eccles, John R. Geddes, Rebecca Hardy, Glyn Lewis, James MasonAbstract:BACKGROUND: Selective serotonin Reuptake inhibitors are thought to have better discontinuation rates (i.e. less people dropping out) than tricyclic and heterocyclic antidepressant drugs. It is important to quantify the drop-out rates of different antidepressant drugs in order to have a better understanding of the relative tolerability of these drugs. OBJECTIVES: To assess the comparative tolerability of selective serotonin Reuptake inhibitors and tricyclic/heterocyclic antidepressant drugs. SEARCH STRATEGY: We searched the Cochrane Collaboration Depression, Anxiety and Neurosis Controlled Trials Registers (1997 to 1999), MEDLINE (1966 to 1999), EMBASE (1974 to 1999) We also searched specialist journals, the reference lists of relevant papers and previous systematic reviews, conference abstracts and government documents. Representatives of the pharmaceutical industry were contacted. SELECTION CRITERIA: Parallel group randomised controlled trials comparing selective serotonin Reuptake inhibitors with tricyclic or heterocyclic antidepressants in people with depression. DATA COLLECTION AND ANALYSIS: Two reviewers independently extracted data and a third reviewer checked any cases of disagreement. MAIN RESULTS: We included 136 trials. The selective serotonin Reuptake inhibitors showed less participants dropping out compared to the tricyclic/heterocyclic group (odds ratio 1.21, 95% confidence interval 1.12 to 1.30). A statistically significant difference was found in total drop-outs between the selective serotonin Reuptake inhibitors and the old tricyclics as well as the newer tricyclics. When the selective serotonin Reuptake inhibitors were compared to the heterocyclic antidepressants, there was a non significant difference favouring the selective serotonin Reuptake inhibitors. The poor tolerability profile of the old tricyclics was explained by differences in drop-outs for side-effects, but not for inefficacy. REVIEWER'S CONCLUSIONS: Whilst selective serotonin Reuptake inhibitors do appear to show an advantage over tricyclic drugs in terms of total drop-outs, this advantage is relatively modest. This has implications for pharmaco-economic models, some of which may have overestimated the difference of drop-out rates between selective serotonin Reuptake inhibitors and tricyclic antdepressants. These results are based on short-term randomised controlled trials, and may not generalise into clinical practice.
